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ABSTRACT
Pathogens continue to evolve m echanisms of avoiding efforts to
control their spread. Treatm ent w ith exogenous antim icrobials often occurs
after the pathogen has reproduced extensively in the host. In the case of
m am m als, the im m une system m ay not be fully m obilized for 72 h after the
detection of foreign antigen. However, within 24 h of presentation of
antigen by antigen-presenting cells to resting thym us-derived lym phocytes
IL2 is produced. A class of broad spectrum antimicrobial peptides which
constitute a major com ponent of the insect im m une system has been
described and characterized. Called "cecropins", they are relatively non-toxic
to norm al cells from m ulticellular organisms but are toxic to a w ide range of
bacteria, protozoa, and fungi as well as infected and abnorm al cells. The
experim ents presented here describe the construction of a plasm id vector
and transcription of mRNA for a cecropin-class synthetic lytic peptide, Shiva
1, under control of the m ouse IL2 prom oter/enhancer and linked to the IL2
signal sequence. Twenty-eight lines of transgenic mice were produced by
pronuclear injection of a BamHI fragm ent containing from -593 to +110 of
the 5' flanking region of mouse interleukin 2 gene including the peptide
signal sequence, Shiva 1, and the SV40 polyadenylation signal and splice
site. By a reverse-transcription polymerase chain reaction (RT-PCR) assay, it
w as determ ined that two lines of transgenic mice w ere produced whose
spleen derived lymphocytes could be induced to transcribe and m ature
mRNA for Shiva 1 by exposure to 3.25 (ig/m l of concanavalin A.

v

In

addition, one of the lines showed evidence of in vivo expression. Since the
controlling regions of the IL2 enhancer and amino acid sequence of the
signal peptide are highly conserved am ong hum ans, mice, cattle, and sheep,
it is likely that this recom binant gene will function in a variety of m am m als.
Studies to assess im m une system enhancem ent of the mice are ongoing.

INTRODUCTION
Finding m ore efficient ways of combating disease both in hum ans and
the plants and animals we depend upon for food and fiber has been and is a
prim ary concern of biological research. Pathogens repeatedly elude
treatm ents necessitating constant innovation. Bacteria once susceptible to
com pounds such as sufam ethazine, penicillin, and streptom ycin are
evolving resistant strains. Concerted efforts by w orld w ide medical
researchers have had little success in combating viral infections once they
become established, w ith the notable exceptions of the deoxynucleotide
analogs such as 3'-azidothym idine (AZT) against the hum an
im m unodeficiency virus and 9-[[Hydroxy-l-(hydroxym ethyl)ethoxy]m ethyl]guanine (gancyclovir) and acycloguanosine (acyclovir) against herpes virus.
Likewise, cancer remains difficult to treat successfully. Com binations of
surgery, radiation therapy, and hightoxic chemicals are typically used.
H ow ever, they often cause severe damage to healthy tissue seading to
undisirable side effects and are far from 100% effective.
One problem w ith treatm ent is that the disease is often not detected
until after the organism or m alignant cell has m ultiplied extensively in the
host. By then, the host's own genetically coded im m une defenses have been
m ustered for the battle and, in the case of mam m als, the first line is engaged.
Lymphocytes and macrophages are concentrated at the site of challenge and
the first signals in the im m une system activation pathw ays have been sent
an d received.
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Genetic engineers are investigating m ethods for increasing the
effectiveness of the natural im m une system. Antim icrobial com pounds
genetically delivered to the pathogen when it is first detected by the host's
im m une system w ould bolster resistance. In the case of m am m als, the ideal
systems in w hich to have expression of an antimicrobial w ould be the blood
an d lymph.
It w as the goal in this set of experiments to design and im plem ent
such a system. The scheme relies on two basic components. The first is a
synthetic antimicrobial peptide of the cecropin class, Shiva 1. The cecropins
have been show n to be toxic to a broad spectrum of pathogens and som e
transform ed cells. The second is the prom oter and enhancer of the
endogenous lym phokine, interleukin 2, norm ally produced by helper
thym us-derived lymphocytes (helper T cells) in response to im m une system
challange.

REVIEW OF THE LITERATURE
INTERLEUKIN 2
Interleukin 2 (IL2) is an im portant signaling protein whose
production in helper T lymphocytes (Fitch, 1992) peaks w ithin 24 hours (h;
Fletcher and June, 1992) of the presentation of a specific foreign antigen by
antigen presenting cells in the m am m alian im m une system . The prim ary
role of IL2, w ithin the present understanding, is as a grow th factor
supporting proliferation of cytotoxic T cells, natural killer (NK) cells, helper
T cells, bone m arrow derived lymphocytes (B cells), m acrophages, and
lym phokine-activated killer (LAK) precursors in a paracrine and autocrine
fashion (Delves and Roitt, 1992). Activated T cells conduct the functions of
cell-m ediated im m unity and a subset, helper T cells, secrete IL2 necessary for
B cell production of soluble antibody, hence, hum oral im m unity. M ature
resting T cells continuously circulate from lym phoid tissues (i.e., spleen,
lym ph nodes) via efferent lymphatics into blood and non-lym phoid tissue
then back to lym phoid tissue via the afferent lym phatics (Scollay, 1992).
This w ide circulation exposes even isolated pockets of invading organism s
to a large T cell pool and maximizes the possibility of triggering specific
im m unity dom inated by cytotoxic T cells and B cells.
Activation of T cells starts when antigen processed by B cells (Pike,
1992) or m acrophages is displayed in conjunction w ith major
histocom patability complex (MHC) class I or II. Binding of this complex to
the T cell receptor complex and sim ultaneous interaction of antigen
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presenting cell surface protein CD58 w ith T cell CD2, MHC w ith T cell CD4
and antigen presenting cell B7/BB-1 with T cell CD28 initiates a complex
chain of events leading to secretion of IL2 by helper T cells. The chain begins
w ith the activation of T cell receptor-associated tyrosine kinase, w hich
activates phospholipase C. Phospholipase C cleaves phosphatidylinositol4,5-bisphosphate into a sugar, diacylglycerol, and inositol-1,4,5-trisphosphate
(IP3). The IP3 binds to a receptor inducing the release of intracellular calcium
ion (Ca+2). Diacylglycerol acts in conjunction w ith Ca+2 and phospholipid to
activate protein kinase C (Fletcher and June, 1992). These intercellular
m essengers and T cell receptor and CD2 binding are required for IL2
induction, how ever, a third signal w hich involves interaction of T cell
surface protein CD28 w ith protein B7/BB-1 from the antigen presenting cell,
results in optim al transcription of IL2 (Fraser et al, 1991; G ranelli-Piperno
and Nolan, 1991). Protein kinase C also functions to dow n regulate the
activation cascade by deactivating phospholipase C and dow n-regulating
both phosphotyrosine phosphatase activity and a required transcription
activating protein, AP-1 (Jain et al., 1992b).
W hile T cell activation in general appears to be m ostly independent
of de novo protein production (Taniguchi, 1988), Granelli-Peperno and
N olan (1991) reported that two factors required for initiation of transcription
of IL2, nuclear factor for activated T cells (NF-AT) and AP-1, are sensitive to
the protein synthesis inhibitor anisom ydn in prim ary hum an T cell
cultures. They also found that the two-exogenous-signal requirem ent for
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IL2 production in vitro was also required for the production of NF-AT and
AP-1. NF-AT had previously been found to be specific to T cells (Weiss et
al., 1984; Verweij it al., 1990).
O ther factors which bind to the IL2 prom oter-enhancer and are
required for expression: nuclear factor kappa B (NF-kB), octom er binding
protein 1 (OCT-1) and AP-3. They are constitutively produced and are
know n to be involved in induction of other genes.
The cascade which leads to activation of T cells activates protein
kinase C, which can act on AP-1. This protein is a complex of various
m em bers of the Fos and Jun DNA-binding protein families (Sassone-Corsi et
al., 1988; Jain et al., 1992a: Jain et al., 1992b). Two binding sites for AP-1 have
been identified in the IL2 promoter-enhancer. The proxim al site a t -159
through -151 (relative to the start of transcription) has been show n to have a
m ajor effect on IL2 expression although m utational analysis dem onstrated
that the distal site (-180) also plays a role (Jain et al., 1992a).
The binding sites for OCT-1, AP-1, AP-3, NF- kB, and NF-AT have
been identified and localized in the sequenced m ouse and hum an IL2 5'
regions (Novak et al., 1990a; Novak et al., 1990b). This confirm ed and
refined findings by Fujita et al. (1986) who used deletion m utations of IL2
prom oter-enhancer linked to chloramphenicol acetyltransferase (CAT) to
localize critical cis-acting regions in culture cell extracts. All are located
w ithin 500 bp of the start of transcription, a region 85% conserved betw een
m ouse and hum an genomes (Fuse et al., 1984). In addition, N ovak et al.

(1990b) also identified c/s-acting regions farther upstream . There they
located a negative regulatory region between -1219 and -578 and a positive
regulatory region between -1890 and -1219 bp from the start of transcription
although their mechanism s of action have not been elucidated.
The closely studied portion of the 5' region from -600 to +43 has been
used successfully by several groups to control reporter genes in cross species
in vitro expression experiments (Fujita et al., 1986; Emilie et al., 1989; N ovak
et al., 1990a). There is a convenient PstI restriction endonuclease recognition
site at +40 (8 bp upstream of the start of translation) in the m ouse gene that
w as com m only used to link reporters to the IL2 prom oter-enhancer.
Previous research w ith the IL2 prom oter-enhancer w as not concerned
w ith secretion. However, it was the goal of my research to use the 5' region
carrying the know n specified control sites for m ouse IL2 to target expression
and secretion of the antimicrobial peptide at the location of T cell activation.
The first 20 am ino acids (aa) translated serve as a signal peptide for secretion
of IL2. The aa sequence is highly conserved am ong species as diverse as the
hum an, m ouse, cow, and sheep (Figure 1; Fujita et al., 1983; Kashima et al.,
1985; Cerrette et al., 1986; Goodall et al., 1990; Seow et al., 1990). Com paring
the hum an and the m ouse aa sequence, there was 63% hom ology overall
including the signal peptide (Kashima et al., 1985) but w hen side chain
polarity of unlike aa are considered, signal peptide homology increases to
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M o u se:
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Figure 1. Com parison of IL2 signal sequence am ong four m am m alian
species. There are two different residues reported for #6 aa in sheep
(Goodall et al., 1990; Seow et al., 1990).

80%. The sam e is true of a comparison between m ouse and cattle, m ouse
and sheep, hum an and cattle, and hum an and sheep. U p to 100% hom ology
exists betw een cattle and sheep w ith a possible single m ismatch at aa #6
(Goodall et al., 1990; Seow et al., 1990).
There is the possibility, then, of using the m ouse IL2 prom oterenhancer from -595 and signal sequence across species for production and
secretion of proteins at the site of detection of foreign antigen.
Investigation by Novak et al. (1990b) indicated that there are no
critical c/s-acting transcriptional control elements in either the introns or the
3' flanking region as far dow n stream from the end of the transcript as 5 kb.
Also, the tight control of expression of IL2 involves not only regulation of
transcription and alteration of transcription-initiating factors but
m odulation of the half life of IL2 mRNA. The IL2 3' flanking sequence
contains an AU-rich motif, which confers sensitivity to degradation by
ribonuclease (Malter, 1989; Troutt and Kelso, 1992). For these reasons, it was
not necessary or advantageous to include sequences 3' to the signal peptide
in an IL2 driven transgene for targeted expression.

LYTIC PEPTIDES
Lytic peptides are a group of small cationic peptides capable of
interaction w ith lipid bilayer m em branes causing osm otic d isruption and
cell death (Dawson et al., 1978; Kanellis et al., 1980; E pand et al., 1987;
Lam bert et al., 1989; H irigoyenberry et al., 1990; Rana et al., 1990; W ade et al.,
1990). Bacterial, protozoan, fungal, and eukaryotic cells w ith com prom ised
cytoskeletons or altered m em branes are m ost susceptible to d isruption
(Jaynes et al., 1989; M oore et al., 1994). In various form s they have been
identified in a w ide range of anim als from insects to m am m als and, in
m any cases, are linked to im m unodefense system s. Researchers in the field
generally divide the group into four classes: defensins, m elittins, m againins,
an d cecropins (although, nom enclature is not stan d ard ized an d other small
lytic peptides that do not fit into these classes continue to be discovered).
Defensins, 33 to 99 aa, differ from the other three in that they are
predicted to have a globular secondary structure stabilized by three
intram olecular disulfide bonds as opposed to an a-helical secondary
structure an d the com plete absence of cysteine residues in the other classes
(Selsted et al., 1983; Lam bert et al., 1990). O riginally discovered in rabbit lung
m acrophages and eosinophils, defensins have also been isolated from the
h em o ly m ph of im m unized larvae of the D ipteran, Phormia terranovae.
M elittins, m againins, and cecropins have a com m on m oiety in an
am p h ip athic a-helix of at least 13 aa carrying a high positive charge density
w hen in solution w ith w ater and low concentrations (8 to 20%, v /v ) of a co

solvent such as trifluoroacetic acid or l,l,l,3,3,3-hexafluoro-2-propanol
w hich stabilizes intram olecular hydrogen bonds (M arion et al., 1988; Sipos et
al., 1992). The helix is configured so that one face is covered by residues w ith
hydrophobic side chains w hile the other face is rich in charged and
hydrophilic side chains, m ost com m only lysine an d arginine. The three
differ in their length, location of a-helix w ithin the m olecule, a n d presence
of a p redom inantly hydrophobic region. Representatives of each class have
been fo und to have antim icrobial activity in both the naturally occurring Lisom er a n d the synthetic D-isom er forms (Wade et al., 1990).
A polipoproteins share w ith the m elittins, m againins an d cecropins the
am p h ip ath ic a-helical configuration and m em brane associating
characteristic b u t not the lytic property (Segrest et al., 1983; Srinivas et al.,
1990).
M elittins, the first of the group to be discovered and investigated, are
a m ajor com ponent of bee venom com prising 50% of the d ry w eight.
M elittin from Apis mellifera, the honey bee, consists of 26 aa a n d tw o
p ro p o sed a-helical regions (Dawson et al., 1978). The am phipathic helix is
located in the carboxyl-term inal half w ith a ru n of six hydrophobic aa on the
N -term inal required for lytic activity (H aberm ann, 1972; D aw son et al., 1978).
M elittin and synthetic analogs w hich retained the m elittin charge
d istrib u tion have been found to be strongly hem olytic at 2 to 100 pM in vitro
(Clague an d Cherry, 1988; W ade et al., 1990; A rrow ood et al., 1991a).
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A ppreciable antim icrobial activity occurs in the 0.1 to 3 pM range depending
u p o n the organism and exact com pound. These results indicate a factor of
ten m argin of safety betw een antimicrobial activity a n d cyotoxicity.
C ontrarily, Boman an d Steiner (1981) reported that m elittin w as equally
toxic to bacteria and Chang liver cells .
Perhaps building on the work reported by Gibson et al. (1986) an d
G iovannini et al. (1987), m againins w ere discovered in and isolated from the
skin of Xetiopus laevis, the African clawed frog, by Zasloff (1987) after he
no ted that non-sterile surgery and post-operative care resulted in only
extrem ely rare instances of infection or abnorm al healing. H e an d his
colleagues proceeded to characterize two 23 aa peptides w ith antim icrobial
activity against 11 bacteria an d fungi in concentrations ranging from 5 to 100
p g /m l (2 to 40 pM) yet no detectable hem olytic activity w ith concentrations
u p to 150 p g /m l (60 pM; Zasloff, 1987; Rana et al., 1990). The m againins were
found to be toxic to in vitro grow n m ouse em bryos in concentrations
ranging from 4 pM for one-cell embryos to 40 pM for blastocysts (Schneider
et al., 1988). Using nuclear magnetic resonance spectroscopy, M arion et al.
(1988) determ ined that m againin 2 form s an am phipathic a-helix from Gly-3
to Asn-22 (accounting for nearly its entire length) w hen in solution w ith
w ater an d 2.3% m olar ratio of trifluoroethanol. W ater alone as solvent
yielded only random coils. The three am ino-term inal residues are
hydrophobic; two of them are apparently outside of the helix.
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N aturally occurring m em bers of the cecropin class w ere first isolated
from the hem olym ph of diapause Hylophora cecropia p u p ae, w hich had
been im m unized w ith a m oderate dose of live bacteria (H ultm ark et al.,
1980). Cecrpoins have since been discovered in other L epidopterans (Boman
an d Steiner, 1981; Shiba et al., 1988; M orishim a et al., 1990), D ipterans (Okada
an d N atori, 1983; Engstrom et al., 1993; Rosetto et al., 1993) and m am m als
(Lee et al., 1989). In size, the naturally occurring cecropins range from 33 to
40 aa w ith the first 18 aa form ing the am phipathic a-helix an d the carboxylterm inal half containing long stretches of hydrophobic aa that form a second
a-h elix (A ndreu et al., 1985; Boman et al., 1985; Boman an d H ultm ark, 1987).
Lytic activity against a w ide variety of free living bacteria has been
d eterm ined to be in the range of 0.005 to 7 (xM (Boman and Steiner, 1981;
A n d reu et al., 1983; A ndreu et al., 1985; van H ofsten et al., 1985; Kelly et al.,
1990; M orishim a et al., 1990; Shiba et al., 1990; W ade et al., 1990). Effective
level differs w ith organism and specific peptide w ith no one p ep tid e being
better at killing all tested organisms. N otable resistance to cecropins by
Staphylococcus aureus (M orishima et al., 1990; Shiba et al., 1990; W ade et al.,
1990) an d Cryptosporidium parvum sporozoites (A rrow ood et al., 1991a;
A rrow ood et al., 1991b) has been docum ented. The protozoan pathogens
Plasmodium falciparum and Trypanosoma cruzi w ere also susceptible b u t
req u ired a 10-fold higher concentration than susceptible bacteria (Jaynes et
al., 1988).
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Toxicity to norm al m am m alian cells is low. Bowm an a n d Steiner
(1981) reported that Chang liver cells w ere not lysed by a concentration of
cecropin A or B 300 tim es that needed to kill bacteria. Jaynes et al. (1988)
rep o rted that uninfected Vero cells w ere unaffected by repeated treatm ent
w ith levels of cecropins effective against T. cruzi and P. falciparum (40 pM ),
although cells infected w ith these pathogens w ere lysed. Reed et al. (1992)
rep o rted that m ouse embryos from the one-cell stage to the blastocyst stage
w ere u nharm ed by culture in 10 |iM of a synthetic cecropin B analog, SB-37,
in W hitten's m edium . SB-37 and other synthetic cecropin analogs w ere
toxic to 3T3 cells an d prim ary lymphocytes at 100 pM (Jaynes et al., 1989a;
Reed et al., 1992). The synthesized L- an d D-isomers of cecropin A are non
toxic to sheep erythrocytes w hen applied in excess of 200 and 300 pM ,
respectively (W ade et al., 1990).
Extensive deletion analysis of the cecropin-class peptide lepidopteran
A revealed segm ents critical to lytic activity in 12 different bacterial species
a n d strains (Shiba et al., 1988). Lepidopteran A variants m issing at least the
first six aa w ere inactive as were those consisting of u p to 12 of the am inoterm inal residues. In fact, deletion of Arg-1 alone resulted in a dram atic loss
of lytic activity. A variant consisting of the first 18 aa (Lep 1-18) h ad slight
activity against three bacteria while addition of five m ore residues m arkedly
increased activity against nearly all susceptible species. Deletion of as few as
five residues from the carboxyl-term inal m easurably reduced lepidopteran A
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activity. In a unique experim ent, Shiba and associates linked Lep 1-18 via an
am ide bond at the carboxyl-term inus to aliphatic hydrocarbon chains of
various lengths. They found that the dodecylam ide variant w as nearly as
active as native lepidopteran A underscoring the im portance of charge
distribution as opposed to aa sequence for lytic activity.
Shiba's group w as not the first to synthesize a cecropin. A ndreu et al.
(1983) an d A ndreu et al. (1985) earlier reported preparation of cecropin A, a
37 aa peptide, and deletion and substitution variants used in investigation of
critical segm ents. Removal of the am ino-term inus dipeptide, Lys-Trp, (Cep
3-37) severely reduced antim icrobial lytic activity to less than 13% w hile a
deletion variant m issing the carboxyl-term inus tetra-peptide, Gln-Ile-AlaLys, (Cep 1-33) retained at least 80% activity w hen com pared to synthesized
cecropin A. A lthough deletion of Arg-1 did reduce activity som ew hat, this
variant w as m ore active than Cep 1-33. C arrying the research further, they
p rep ared substitution variants aim ed at disrupting the critical am inoterm inal region. Substitution of Trp-2 w ith a non-arom atic b u t a -h e lix
form ing residue like glutam ic acid resulted in a level of lytic activity low er
than C ep 3-37. In com parison, a variant w ith phenylalanine, another
arom atic, substituted for Trp-2 had essentially no loss in activity an d they
hypothesized that the arom atic group was the critical moiety. R odriguez et
al. (1995) confirm ed that hypothesis. They substituted Trp-2 in a cecropin Blike peptide, Shiva 1, w ith Tyr and found no difference in activity.
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Trp-2, highly conserved in natural cecropins, w as deem ed critical for
activity by A ndeu et al. (1985), how ever, other substitutions th at d isru p ted
the am phipathic a-helix also caused a loss in activity against m any b u t no t
all m icroorganism s. They sum m arized their results by concluding that
different portions of the m olecule m ay be critical for activity against
different organism s and that the full length m ay need to be retained for the
bro ad est activity. To retain lytic activity, cecropins m u st have at least 1) a
basic aa follow ed by an arom atic helix-inducing aa, 2) im m ediately follow ing
the arom atic, an am phipathic a-helix of at least 15 aa w ith a charged face
dom inated by basic residues, and 3) a carboxyl-tail of predom inantly
hydrophobic a-helix-form ing residues from 5 to 17 aa long.
Jaynes and colleagues have responded by system atically designing
cecropin B analogs and testing them for lytic activity and toxicity w ith the
goal of developing corresponding genes for plants that either enhance their
disease resistance (Jaynes et al., 1987,1989a, 1993; Destefano-Beltran et al.,
1991) o r utilize them as bioreactors for synthesizing large quantities of
p ep tid e inexpensively (Jaynes et al., 1988). The first successful attem pts w ere
pep tid es nam ed SB-37, SB-37*, an d Shiva 1 (Jaynes et al., 1988; Jaynes et al.,
1989b). SB-37 has high aa sequence hom ology w ith cecropin B. A single aa
substitution of Val for M et at the eleventh position and addition of a MetPro d ip eptide at the am ino-term inus altered cecropin B to allow
developm ent of a cyanogenbrom ide- cleavable repeat p ep tid e gene p ro d u ct
(Jaynes et al., 1988). Substituting Val-11 for Met-11 also m ay have served to
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stabilize the a-helix since Val has been show n to be a stronger helix form er
(O 'N eil an d DeGrado, 1990). SB-37* has the sam e changes from cecropin B as
SB-37 w ith the additional changes of a lysine to leucine substitution a t the
sixth position and a tryptophan to glutam ate substitution at the second
position.

Recall th at for cecropin A, A ndreu et al (1985) show ed th at Trp-2

to Glu-2 essentially deactivated the peptide. They also dem onstrated that a
change of Lys-6 to Leu-6 destroyed activity against Pseudomonas aeruginosa
b u t h ad no effect on activity against Escherichia coli.

SB-37*, then, was

designed to use as a negative control in toxicity and antim icrobial
experim ents.

SB-37 retained the sam e level of antim icrobial activity as

cecropin B (N ordeen et al., 1992; Jaynes, unpublished data).
Shiva 1 represented a m ore radical departure from cecropin B.
A pproxim ately 60% of the aa residues are different (Figure 2). H ow ever, the
charge distribution, helix-form ing tendencies, am phipathic am ino-half and
hydrophobic carboxyl-half of cecropin B were retained. Again, the M et-Pro
d ip ep tid e w as ad d ed to the am ino-term inus and internal M et residues w ere
avoided. It w as designed specifically "to test w hether or no t the lytic
properties of cecropin-like peptides are highly sequence-dependent" (Jaynes
et al., 1988).
Synthesized Shiva 1 w as tested in various experim ents for toxicity
an d antim icrobial activity w ith SB-37*, SB-37, m elittin, and a m elittin
analog, Hecate 1 (Jaynes et al., 1988,1989,1993; W hite et al., 1989; Kelly et al.,
1990; Reed et al., 1992; Rodriguez et al., 1995). In sum m ary, Shiva 1 w as
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Cecropin B:

AAA TGG AAA GTC TTC AAG AAA ATT GAA AAA ATG
Lys Trp Lys Val Phe Lys Lys lie Glu Lys Met

Shiva-1 :ATG CCG CGC TGG CGT CTG TTC CGC CGT ATC GAC CGT GTT
Met Pro Arg Trp Arg Leu Phe Arg Arg lie Asp Arg val

GGT CGC AAC ATT CGA AAC GGT ATT GTC AAG GCT GGA CCA GCT ATC
Gly Arg Asn lie Arg Asn Gly lie val Lys Ala Gly Pro Ala lie
GGC AAA CAG ATC AAA CAG GGT ATC CTG CGT GCT GGC CCG GCT ATC
Gly Lys Gin H e Lys Gin Gly lie Leu Arg Ala Gly Pro Ala lie

GCG GTT TTA GGC GAA GCC AAA GCG CTA
Ala Val Leu Gly Glu Ala Lys Ala Leu
GCT CTG GTT GGC GAC GCC CGC GCA GTT GGT
Ala Leu Val Gly Asp Ala Arg Ala Val Gly

Figure 2. Com parison of the DNA code and aa sequence of m atu re cecropin
B (van H ofsten et al., 1985) and Shiva-1 (Jaynes et al., 1988). H om ologous
residues are aligned for easier comparison.

found to have broad spectrum antim icrobial activity on the average equal to
SB-37. As is com m on w ith all cecropin variants relative sensitivity w as
unpredictable.

Some tested organism s w ere m ore sensitive to Shiva 1 than

SB-37 and som e were less. M elittin and Hecate 1 w ere bacteriacidal a t low er
concentrations than Shiva 1. Shiva 1 has been reported to be slightly m ore
toxic to eukaryotic cells than SB-37 b u t m uch less toxic than either m elittin
or H ecate 1.
Evaluations of lytic activity against eight im p o rtan t fish pathogens
dem onstrated that Shiva 1 w as effective at betw een 5 nM an d 1 |iM (Kelly et
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al., 1990). AgainstT. cruzi trypom astigotes, the free living form of the
p rotozoan parasite causing C hagas' disease, effective concentration w as 25
pM. It w as also found to be effective in killing T. cruzi infected Vero cells at
100 pM while leaving uninfected control Vero cells unharm ed. Jaynes et al.
(1988) postulated that the intracellular parasite d isru p ted the cell m em brane
m aking infected cells m ore sensitive to lysis.
Jaynes et al. (1989b) hypothesized that transform ed m am m alian cells
m ay be sensitive to lysis by lytic peptides therefore, Shiva 1, SB-37, SB-37*,
an d m elittin w ere tested for cytotoxicity on EL-4 m ouse thym om a, SP2
m yelom a, U937, and D audi-B urkitt's lym phom a transform ed cell lines;
norm al hu m an prim ary lym phocytes; an d donkey derm al cells (an
u ntran sform ed fibroblast cell line). C om pared to norm al h u m an
lym phocytes and donkey derm al cells, transform ed lines d id prove to be
m ore sensitive to lysis w hen exposed to 100 pM SB-37 for 60 m inutes (min)
w ith viability reduced 35 to 90% depending upon the line. M elittin d id not
differentiate betw een transform ed and norm al cells being highly toxic to all
cell lines tested. Also, it w as found that treatm ent of donkey derm al cells
w ith either 5 m g /m l cytocalasin D or 10 pM colchicine, both cytoskeletal
inhibitors, greatly increased their sensitivity to 100 pM Shiva 1 or SB-37.
M oore et al. (1994) also reported testing cecropin B, cecropin P I (from
pig intestine), and Shiva 1 on various cell lines in vitro an d finding tw o cell
lines w ith the m ultidrug-resistant phenotype to be sensitive to the peptides.
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Also, m ice carrying m urine ascetic colon adenocarcinom a cells h ad
increased survival tim e w hen treated w ith cecropin B.
There is one report available docum enting the expression of a Shiva 1
gene conferring disease resistance. Jaynes et al. (1993) described transferring
a gene for Shiva 1 controlled by a potato proteinase inhibitor II (Pill)
prom oter via Agrobacterium Ti-plasm id-m ediated gene transfer into
tobacco plants. The prom oter is induced by w ounding (either m echanically
or by a pathogen) in the w ounded leaf and in other undam aged leaves,
stem s, an d roots. Expression is undetectable in unharm ed transgenic tobacco
plants m aking it an ideal prom oter for delivery of an antim icrobial p eptide
(Sanchez-Serrano et al., 1987). Transgenic plants w ere challenged w ith
Pseudomonas solanacearum, a vascular tissue pathogen th at u p o n infection
causes severe w ilting and which w as found to be susceptible to killing in
vitro by 40 fiM of Shiva 1. Tobacco lines testing positive for Shiva 1
expression by northern and w estern analysis exhibited delayed appearance of
sym ptom s of infection that w ere ultim ately less severe than those on
control plants. By w eek four, 55% of the control plants had died w hile no
Shiva 1 plants had succum bed to the disease. H ow ever, plants expressing
either SB-37 (Jaynes et al., 1993) or cecropin B (Florack et al., 1995) under the
control of a constitutive prom oter, 35S cauliflower mosaic virus 5' region,
w ere n o t resistant to P. solanacearum.
Shiva 1 w as chosen as the peptide to be expressed in the transgenic
mice in these experim ents because it has broad antim icrobial activity, it is
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relatively non-toxic to norm al lym phocytes an d fibroblasts, an d it has been
show n to be effective in enhancing disease resistance w hen expressed as a
transgene.

MATERIALS AND METHODS
CONSTRUCTION OF THE VECTOR
C loning Of M ouse Interleukin 2 P rom oter/E nhancer
A portion of the m ouse IL2 gene from -593 to +110 containing the
k n o w n prom oter and enhancer regions as well as the portion of open
read in g fram e coding for the protein signal sequence w as am plified from
m ouse genom ic DNA using polym erase chain reaction (PCR; Saiki et al.,
1988). Tem plate DNA w as extracted from 3T3-Swiss Albino fibroblasts
(ATCC #CCL92) using the m ethod of Higuchi (1989). Briefly, susp en d ed cells
w ere ad d ed to 200 pi of 50 mM KC1,10 m M tris(hydroxym ethyl)am inom ethane (Tris)-HCl pH 8.3, 2.5 mM MgCl2, 0.1 m g /m l gelatin (Sigma G2500), 0.45% Tween 20 (M allinkrodt) and 0.45% Triton X-100 (M allinkrodt)
an d frozen at -20°C until used. The sequence of prim ers w as determ ined by
stu d y of the m ouse genomic IL2 sequence published by Fuse it al. (1984) for
the dow nstream prim er in the signal peptide coding region an d N ovak et al.
(1990) for the upstream prim er in the enhancer. The enhancer b u t not the
coding region w as also available as EMBL accession num ber X52618, w hich
eased exploration of the sequence. Also, the prim ers w ere designed so that
the resulting PCR fragm ent contained a Sail site at the 5' end an d a Bglll site
at the 3' end to facilitate subcloning. Prim er sequences w ere S'-TAGATCTTGC-GCTGT-TGACA-AGGAG-3' for the dow nstream prim er (IL2-1) and
5'-AGTCG-ACAAC-GACAA-AATAG-TACCT-3' for the u p stream prim er
(IL2-2). (See Figure 3 for a listing of prim ers used in this stu d y an d their
20
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expected pro d u ct lengths.) PCR conditions w ere 1.5 m M MgCl2 /10 m M TrisHC1, 200 nM each prim er, 2 jxM each deoxynucleotide triphosphate (dNTP;
Perkin-Elm er), 50 m M KC1, 0.01% (w /v ) gelatin, 500 ng of m ouse genom ic
DNA an d 2.5 units Am pliTaq DNA polym erase (Perkin-Elmer) in a reaction
volum e of 100 pi. A Perkin-Elm er Cetus DNA Therm al Cycler w as
program m ed w ith a 3 m in 95°C initial denaturation step; 30 cycles of 1 m in
at 95°C, 1 m in at 58°C, an d 1 m in at 74°C; and a final elongation step of 7 m in
at 72°C. The sam ples were then held at 4°C until evaluated.
The resultant 715 bp DNA contained the m ajor u p regulatory cisacting sequences of the 5' flanking region, the TATA box, the PstI site at +43,

IL2-1:
IL2-2:
IL2TRANC:
MH3UP:
MH3DN:
SHIVAlUP:
SHIVAlDN:

TAGAT
AGTCG
CACCC
CCTGA
TTCCG
AACCA
AGATC

CTTGC
ACAAC
TTGCT
GCGCT
GGGGA
ACTGC
TACCA

GCTGT
GACAA
AATCA
CTCGA
TGGTG
GCGGG
TGCCG

TGACA AGGAG
AATAG TACCT
CTCCT
ACCGC
GTGT
CGTCG
CGCTG

antisense
sense
sense
sense
antisense
sense
antisense

IL2-2/IL2-1: 715 bp; am plified IL2 prom oter for cloning.
IL2TRANC/SHIVA1DN: 235 bp; am plified from the IL2 start of transcription
to the last codon of Shiva 1 in the recom binant transgene an d u sed for
detection of IL2-Shiva 1 mRNA and DNA screening.
SHIVA1UP/SHIVA1DN: 125 bp; am plified Shiva 1 open reading fram e and
used to screen for the presence of the transgene in founder mice.
M H 3U P/M H 3D N : 283 bp; am plifies a fragm ent of m ouse hom eobox 3
(Rubin et al., 1986) an d used as a positive control in DNA screening.
IL2-2/SHIVA1DN: 840 bp; amplifies fusion gene IL2 p ro m o te r/e n h an c e r
plus Shiva 1
Figure 3. Sequences of PCR prim ers used in this study; the pairings, region
am plified, and the predicted length of the products are show n. Sequence is
5' to 3'.
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a n d the 21 aa signal peptide from m ouse IL2, an d new restriction sites a t the
5' an d 3' ends.
A lthough this schem e introduces code for an intervening series of
fo u r aa (alanine-arginine-serine-threonine) betw een the signal p ep tid e an d
Shiva 1, d u e to the hydrophilic nature of these residues it w as p redicted that
the change w ould not effect activity substantially. N one of these residues
are specifically a-helix destabilizers. Helix-form ing tendency for alanine an d
arginine are high while that of serine is m oderate. H ow ever, threonine
coupled to m ethionine-proline, the first tw o aa residues of Shiva 1 w ould
likely preclude extension of the am phipathic a-helix to the am ino-term inus
(O 'N iel an d D eG rado, 1990). N evertheless, prediction of secondary structure
in a highly polar context, such as this is, w ould be difficult at the current
level of know ledge (Lyu et al., 1990), especially considering th at the
h y d ro p hobic m icro-environm ent at the m em brane interface plays a role in
form ation of the am phipathic a-helix of cationic m em brane associating
pep tid es (M arion et al., 1988; Sipos et al., 1992).
The PCR product w as purified and m ade blunt ended using the
double G eneClean protocol and reagents provided in the G eneClean® II kit
(BiolOl). Briefly, 300 |xl of N al w as com bined w ith the 100 |xl reaction a n d 15
(xl o f G lass Milk® (silicate spheres in aqueous suspension that have a strong
affinity for double stranded DNA >50 bp long) an d held on ice for 10 m in
w ith occasional gentle mixing. The suspension w as centrifuged to pellet the
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b ead s an d the pellet w ashed three tim es w ith N ew W ash® solution. The
D N A w as eluted from the beads w ith 20 pi H 20 and a 10 m in 55°C
incubation. A second elution w as also perform ed using 50 jxl of H aO.
C lark (1988) has show n that Taq DNA polym erase along w ith Klenow
enzym e, D N A polym erase I from Saccharomyces cerevisiae, an d others m ay
ad d bases to the 3' end of double stranded DNA independent of tem plate
w hich inhibits blunt end cloning of these fragm ents. Also, the prim ers used
in this PCR reaction did not contain a 5' triphosphate group. Therefore, to
get m axim um cloning efficiency 25 pi of the elute, 7 pi from the first and 18
pi from the second elution, were used in a reaction designed to b lu n t end
an d phosphorylate the PCR product. Ten units (U) of polynucleotide kinase
(Prom ega) an d 10 U of Klenow enzym e (Promega) w ere ad d ed to the elute in
a buffer com posed of 50 mM Tris-HCl pH 7.6,10 mM MgCl2, 1 m M
d ithiothreitol (DTT), 10 m M adenosine triphosphate (ATP), 20 nM each
dN TP, a n d 50 p g /m l high purity bovine serum album in fraction 5 (BSA;
M iles Laboratories) in a total volum e of 100 pi and incubated at 37°C for 1 h.
After ad dition of 1 pi of 0.5 M ethylenediam inetetraacetic acid (EDTA) to
stop the reaction, the DNA w as rem oved from the solution using a second
G enC lean procedure sim ilar to the first.
H 20 w as used to re-suspend the DNA.

A single elution step in 25 pi of
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The PCR product was then cloned into the Smal site of pUC18
(M essing, 1983; United States Biochemical; Figure 4). A m olar ratio of
approxim ately three parts pUC18 to four parts IL2 e n h an cer/p ro m o ter (a 3:1
m ass ratio) was used in a ligation reaction containing 150 ng pUC18 Sm al
digest, 50 n g IL2 DNA, 20 mM Tris-HCl p H 7 .6 ,5 m M MgCl2, 5 m M DTT, and
50 (ig /m l BSA (Sambrook et al., 1989). Ligation w as perform ed overnight at
16°C.
Transform ation of E. coli strain DHSaMCR (Life Technologies) w as
perform ed w ith frozen com petent cells prepared and utilized exactly as
described by Sam brook et al. (1989). This strain has a nonfunctional /3galactosidase (p-gal) b u t allows a-com plem entation for a retu rn of function
(U llm ann et al., 1967). The plasm id pUC18 contains lacZ' u n d e r control of
the lac prom oter (lacl) which can be induced by isopropyl-thiogalactoside
(IPTG). Insertion of a foreign fragm ent in the Smal site uncouples lacZ'
from the prom oter preventing (3-gal function. This allow s screening of
clones containing an insert by exposing colonies to the (3-gal substrate 5bromo-4-chloro-3-indolyl-[3-D-galactopyranoside (Xgal), w hich turns blue
u p o n cleavage by [3-gal. Colonies containing plasm id w ith no insert are blue
w hereas those containing plasm id w ith insert are white.
O ne h u ndred nanogram s of ligated DNA w as u sed for the
transform ations. O ne h u ndred centim eter diam eter SOB-agar (Sam brook et
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Figure 4. Construction of pILSHIX/neo and source of IL 2/Shiva 1 gene
for pronuclear injection of m ouse pronuclear stage embryos. Plasm ids and
fragm ents are to scale in Figures 3 and 4. pUC18 w as purchased from US
Biochemical, pM ClneoPolyA from Stratagene, and pShiva-1 w as as
described by Jaynes et al. (1993).
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al., 1989) culture plates containing 100 p g /m l ampicillin and spread w ith 40
|xl of 2% Xgal and 0.1 M IPTG as described in Sam brook et al. (1989) w ere
u sed to culture 200 pi of the cell suspension. A pproxim ately 40% of the
colonies w ere white. Eight w hite colonies w ere grow n over night in LuriaBertani M edium (LB; Sam brook, 1989) and alkaline lysis m inipreparations
perform ed (Birnboim and Doly, 1979). Isolated plasm id w as digested w ith
H in d lll (Prom ega) and those clones w hich appeared to contain the correct
size DNA w ere digested w ith Bglll (Pharmacia).
A single clone which cut w ith Bglll w as further investigated w ith
restriction endonuclease digest. The m ouse IL2 p ro m o te r/e n h an c e r
contains a convenient PstI site 43 bp inside the open reading frame. This site
has been used in transient expression studies of prom oter function by
N ovak et al. (1990) and Emilie et al. (1989). It w as used here to check the
integrity and orientation of the recom binant DNA. In addition, Bglll/EcoRI
(Life Technologies), Sail, and B glll/PstI digests w ere perform ed.
Incorporation, restriction site integrity, and orientation w ere consistent. The
resulting plasm id was nam ed "pUCIL".
Integration of Shiva 1 w ith IL2
The Shiva 1 gene had been synthesized and cloned into the plant
plasm id vector pMON530 by Jaynes and others in the D epartm ent of
Biochemistry, Louisiana State University (Jaynes et al., 1993; DestefanoBeltran et al., 1991). The Shiva 1 fragm ent w as digested from the plasm id,
separated by agarose gel electrophoresis (40 mM Tris-acetate, 1 m M EDTA

(TAE) buffer), and eluded by the procedure described by Z hu et al. (1985).
Plasm id pUCIL w as digested w ith Bglll and EcoRI and purified w ith the
GeneClean II procedure. The glass beads of the GeneClean kit bind DNA
fragm ents sm aller than 50 bp poorly allow ing rem oval of u n w a n ted sm all
fragm ents from a solution. The unw anted Bglll-EcoRI fragm ent of pUCIL is
only 16 bp, so subjecting this solution to GeneClean reduced the
recom bination of the vector in the subsequent ligation. Shiva 1 fragm ent
(128 bp) and vector (3385 bp) were com bined in a ligation reaction at a 2.25:1
m olar ratio using 30 ng of pUCIL, 2.5 ng of Shiva 1,10 Mg/ml BSA (Sigma), 1
W eiss u n it of T4 ligase (Promega), and Prom ega Ligase Buffer in a 10 |il
reaction. DHSocMCR w ere transform ed as described above using one half of
the ligation reaction. Colonies were screened as above using PstI an d EcoRI
digests and one clone w as chosen to use in further experim entation
(pILSHI).
Sequencing IL2-Shiva 1 Gene
There w as a concern that replication using Thermus aquaticus (Taq)
DNA polym erase w hich has no 3' to 5' exonuclease proofreading activity
w o u ld cause substitution m utations that could interfere w ith the proper
function of the IL2 region (Tindall and Kunkel, 1988). Also, although a
clone of Shiva 1 w hich had been inserted into pUC19 had been sequenced
and found to agree w ith the sequence program m ed into the D N A
synthesizer (data not shown), that clone w as two subclones rem oved from
pILSHI. In addition, the correct sequence at the interface of the IL2 signal
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w ith Shiva 1 w as critical for correct in fram e translation. Therefore, a
definitive determ ination of the sequence of the IL2-Shiva 1 gene w as m ade
by D N A sequencing using the dideoxynucleotide m ethod pioneered by
Sanger et al. (1977) bu t m odified to accom m odate double stranded tem plate
(Sam brook et al., 1989; U nited States Biochemical, 1990). Sequencing w as
p erfo rm ed from both ends using the M l3 U niversal and Reverse prim ers
(US Biochemical) as well as the IL2-1 prim er (Figure 3) for better resolution
of the m iddle of the construct. A set of reactions using inosine in place of
guanosine w ere included to reduce band com pression in regions of strong
in trastran d secondary structure (United States Biochemical, 1990).
Plasm id DNA previously isolated by m iniprep w as further purified by
treatm en t w ith phenol pH 8.0, phenol:chloroform :isoam yl alcohol (25:24:1),
an d three treatm ents of chloroform . It w as then precipitated w ith ethanol
u sin g sodium acetate as the m onovalent cation source, resuspended in TE
buffer p H 7.6 (10 m M Tris-HCl pH 7.6,1 m M EDTA pH 8.0; Sam brook et al.,
1989), an d quantitated by m easuring absorbence at 260 nm. Twenty-five
nanogram s of pILSHI w ere treated w ith 100 mM N aO H at room tem perature
for 5 m in then ethanol precipitated using am m onium acetate, w ashed twice
w ith 70% ethanol, dried in a vacuum , and resuspended in w ater purified
th ro u g h deionization and reverse osm osis cartridges to a conductivity of at
least 17.5 MO-cm (type 1 water).
Five nanogram s of denatured DNA were transferred into each of
eight tubes, to m ake a set of four reactions for each prim er. Prim ers w ere

ad d ed , the solution heated to 65°C for 2 m in in a heat block then cooled
slow ly by placing the block on the bench at room tem perature until the
tem p erature d ro p p ed below 30°C to allow prim ers to anneal to the tem plate.
The labeling reaction w as carried out as described in the Sequenase II Kit
(U nited States Biochemical) using a labeling mix diluted 1 to 5 and
Sequenase T7 DNA polym erase diluted 1 to 8 to allow reading of 30 to 200
bases from the prim er and in the presence of 6.25 jj.Ci of a 3SSdATP. A fter 6
to 7 m in at room tem perature, term ination m ix containing the
corresponding dideoxynucleotide w as added to each and the incubation
continued for an additional 5 min at 37°C. To reduce artifact bands, a
m ixture of 1 mM of each dNTP to a final concentration of 0.05 m M an d 8.5 U
of term inal deoxynudiotidyl transferase was added to each reaction and
incubation extended 30 m in (Fawcett and Bartlett, 1990).
A ddition of the Polyadenvlation Signal and Splice Site
The Sim ian Virus 40 polyadenylation signal and splice site (SV40
polyA & splice) w ere added to help m aintain integrity of the transcript
d u rin g translation (Figure 5).
Tw enty-tw o m icrogram s of the superlinker cloning vector pSL1190
(Pharm acia) w as digested w ith BamHI (Pharmacia) and Sail (Pharm acia) an d
1.2 |ng of m am m alian expression vector pMSG w as digested w ith BamHI and
Xhol (N ew England Biolabs) in One-Phor-AU (OPA) buffer (Pharmacia).
C om plete digestion w as confirm ed by agarose gel electrophoresis. The digest
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Figure 5. Construction and isolation of an SV40 polyadenylation signal
an d splice site w ith EcoRI site designed to link to the 3' end of Shiva 1.
Plasm ids and fragm ents are to scale in Figures 4 and 5. pSL1190 and
pMSG w ere purchased from Pharmacia Biotechnology.
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of pMSG yielded fragm ents of 36,848, and 3386 bp and the digest of pSL1190
yielded fragm ents of 37 and 3485 bp. This rem oves the SV40 polyA & splice
(848 bp) from pMSG and prepares pSL1190 (3485 bp) for receipt of the
fragm ent.
After deactivation of restriction endonucleases by incubation at 85°C
for 20 m in an d phenol extraction followed by ethanol precipitation, an equim olar concentration of the tw o restriction digests, 250 n g of pSL1190 and 500
n g of pMSG w ere m ixed in a 10 jxl ligation reaction using 3 U of T4 ligase
(Prom ega) in IX OPA buffer w ith 1 mM ATP. The reaction w as incubated
overnight at 16°C in a heat block surrounded by 4°C am bient tem perature.
Ligation of Xhol and Sail com patible cohesive ends destroyed the Sail site of
pSL1190.
Frozen com petent E. coli strain DH5aM CR cells w ere transform ed
u sin g the m ethod previously described (Sambrook et al., 1988).
M inipreparations of colonies grow n in SOB m edium (Sam brook et al., 1988)
containing 100 m g /m l am picillin were screened using a B am H I/EcoR I
digest. Religated pMSG yields three fragments: 751, 2250, and 4625; religated
pS11190 yielded two fragm ents 58 and 3364 bp; the correct construct,
pSLl 190/Pol A, yielded two fragments: 908, and 3364 bp.
Two prom ising clones of 20 the screened w ere digested w ith Xbal
(N ew E ngland Biolabs) an d Spel (Life Technologies) in IX OPA® buffer and
checked on an agarose gel. A t this point, one clone w as discarded w hen it
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failed to cut w ith either enzyme. To get a fragm ent bounded by EcoRI and
A fllll that could be ligated into a pILSHI fragm ent having identical cohesive
ends (Afllll has m ultiple recognition sequences), tw o Afllll sites from the
m ultiple cloning site that has a different m iddle pair of bases in the cohesive
en d had to be rem oved. The X bal/Spel fragm ent contains these Afllll sites
an d the cohesive ends of Xbal and Spel are com plem entary allow ing easy
religation. The fragm ent rem oved was 144 bp and contained a unique PstI
site. Therefore, to reduce background in the follow ing ligation, the reaction
products w ere further digested w ith PstI in IX OPA for l h at 37°C and chilled
on ice im m ediately before adding 3 Weiss units of T4 ligase and ATP to a
final concentration of 1 mM.
E. coli w as transform ed and clones screened as described above using a
Bglll (Pharm acia)/H indIII(Prom ega) double digest in Prom ega buffer B an d a
PstI (Pharm acia) digest. N ine of ten clones w ere identified as having the
correct deletion; one w as selected and nam ed "pSLpolAA".
Plasm ids pSLpolAA and pILSHI were digested w ith EcoRI (Life
Technologies) and Afllll (N ew England Biolabs) in REact4 buffer (Life
Technologies). The desired fragm ent from pSLpolAA w as 1376 bp as the
insert and that from pILSHI w as 3164 bp as the vector. These w ere gel
purified using 1% SeaKem GTG® agarose (EMC), TAE electrophoresis
buffer, an d FMC's Spinbind® columns as directed by the com pany. The
isolated fragm ents w ere com bined in a m olar ratio of 2 m oles of insert to 1
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m ole of vector and an approxim ate total of 200 ng of DNA. T ransform ation
an d screening identified nine of nine colonies tested contained the correct
plasm id. One w as selected and nam ed "pILSHIX".
Insertion of N e o Cassette
To use the construct to stably transfect m am m alian cells in vitro, a
selectable m arker, a neom ycin phosphotransferase (Berg et al., 1975)
expression cassette w as then cloned into the Sail site in pILSHIX upstream of
the IL2 p ro m o ter/en h an cer and oriented to transcribe in the opposite
direction from the Shiva 1 cassette. This cassette from pM CIneoPOLA
consisted oineo u n d er control of the herpes virus thym idine kinase
p ro m o ter w ith transcript processing using a synthetic polyadenyl-ation
signal (Thomas and Capecchi, 1987; Stratagene). Plasm id pM CI w as digested
w ith Xhol and Sail in IX OPA® buffer and pILSHIX w as digested w ith Sail in
Sail buffer (New England Biolabs). After testing for com pletion of reaction,
both reactions w ere phenol extracted and ethanol precipitated. They w ere
then m ixed in a one to one m olar ratio an d ligated (2 h at 15°C) then used to
transform E. coli described above. HindHI digest of m inipreps indicted tw o
of 24 colonies tested had the correct clone. The resulting plasm id w as
n am ed "pILSH I/neo".
PRODUCTION OF TRANSGENIC MICE
D N A Preparation
A 1713 bp BamHI fragm ent of pILSHIX containing only !L2fShiva-l
w as used for the production of transgenic mice. D N A w as isolated using
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alkaline lysis and purified by passage through a Spinbind colum n (FMC) and
eluted in 50 pi m icroinjection buffer.

M icroinjection buffer consisted of 10

m M Tris pH 7.4, 0.15 mM EDTA in type 1 w ater carefully filtered through a
0.2 pm pore-size m ixed esters of cellulose filter (M illipore) in a biosafety
hood to avoid contam ination by dust w hich could clog the m icroinjection
needle.

RNase A (Sigma) w as added and plasm id digested w ith BamHI in

60 p i volum e of REact 3® (Life Technologies). The fragm ents generated
w ere 1713 and 2758 bp which w ere separated on a 1% TAE agarose gel. The
1713 bp band w as excised from the gel and the DNA isolated using the
Spinbind® system . Microinjection buffer w as again used for elution from
th e colum n.
DN A w as further purified w ith m icrodialysis. A 25 pi d ro p of IL2Shiva 1-SV40 polyA DNA solution was pipetted to the center of a 27 m m
d iam eter, 0.025 pm pore-size m ixed esters of cellulose m em brane (M illipore)
w hich w as floating on 10 m l of m icroinjection buffer in a 100 m m
polystyrene petri dish. Dialysis w as carried o u t for 48 h against tw o changes
of m icroinjection buffer during w hich time the dish w as sealed w ith
Parafilm ® (Am erican Can). At the end of the period, an additional 10 pi of
m icroinjection buffer w as added to the sam ple spot, pipetted u p a n d d o w n to
m ix an d the solution transferred to a m icrocentrifuge tube. Tw o m icroliters
o f the solution w as stained w ith Hoechst 33258 an d used to determ ine the
concentration by spectrofluorom etry using a TKO 100 in stru m en t (Hoefer)
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and the protocol supplied by the m anufacturer. The rem aining solution w as
then d iluted to 2 n g /fil final w orking concentration w ith m icroinjection
buffer.
Em bryo Production and Pronuclear Injection
Transgenic mice w ere produced using the stan d ard protocol used
routinely by M orrey and his associates w ith the AIDS Research P rogram at
U tah State University (Morrey et al., 1993; M orrey et al., 1992; M orrey et al.,
1991). Briefly, tw o groups of 20 four-week-old female FV B /N strain mice
(Taketo et al., 1991; Teconic Farms, NY) w ere synchronized and
su p ero vulated w ith pregnant m are serum gonadotropin (PMSG; Sigma) and
h u m an chorionic gonadotropin (hCG; Sigma). Seven international units
(IU) of each horm one in 0.1 ml of sterile norm al saline w ere given by
intraperitoneal injection to each m ouse. PMSG and hCG w ere adm inistered
67 to 68 h and 20 to 21 h, respectively, prior to rem oval of em bryos from the
m ouse. M ating w as perform ed by proven FV B /N strain males. The
follow ing m orning, m ated mice w ere sacrificed by hum ane m eans (cervical
dislocation or CO2 asphyxiation. The embryos w ere collected from the
oviducts, and held in M2 m edium (Pratt, 1987). Em bryos w ere m aintained
at 37°C before, during, and after m anipulation. U nder 400x Hoffm an optics,
em bryos w ere m icroinjected w ith 2 n g /(il DNA solution into the m ale
a n d /o r female pronuclei until the nuclear m em brane visibly sw elled.
W ithin 2 h after injection, em bryo transfer surgery w as perform ed on

tribrom oethanol (Avertin) anesthetized (Pratt, 1987) Sw iss-W ebster strain
fem ales, w hich had been m ated 12 to 16 h earlier to vasectom ized ICR strain
males. Seven-week-old Swiss-W ebster females w ere used as the foster strain
because of their superior m aternal ability. The ICR strain h ad been
previously b u t they occasionally cannibalized their litters especially w hen
d istu rb ed w ithin a few days of giving birth; this never h appened w ith the
Swiss-W ebster foster m others. Approxim ately 15 em bryos w ere transferred
to each oviduct of each recipient using a finely d raw n glass pipette.
SCREENING TRANSGENIC MICE AND DETECTION
OF SHIVA 1 EXPRESSION
Initial screening of possible transgenics w as m ade using PCR. After
individual identification by toe clipping, 1 to 2 cm of tail w as cut from each
m ouse w ith sharp clean scissors. The tail piece w as subjected to overnight
digestion in 500 pi of tail lysis buffer (100 m M Tris-HCl, 5 m M EDTA, 0.2%
sodium dodecyl sulfate (SDS), 200 mM NaCl, 14 p g /m l proteinase K, pH 8.0).
U ndigested debris w as rem oved by centrifugation at 20000 x g an d genom ic
DNA w as precipitated from the supernatant w ith isopropanol. The pellet
w as rinsed in 70% ethanol, dried in air, and resuspended in 200 pi TE p H 7.6.
The suspension w as heated to 65° C for 1 h to deactivate residual proteinase
K and aid in dissolving the DNA.
Five m icroliters of this solution were used in PCR along w ith 20 pM ol
each SHIVA1UP and SHIVA1DN prim ers (Figure 3), 2.5 U Taq DNA
polym erase (Promega), GeneAm p PCR Buffer (Perkin Elmer), an d 0.2 m M
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each dNTP. The reaction w as perform ed at 94°C for 3 m in to denature
genom ic DNA; 25 cycles of 94°C for 1 m in, 58°C for 1 min, and 72°C for 1.5
m in; and a final elongation period of 5 m in at 72°C. The reaction products
w ere evaluated in gels consisting of 1.5% agarose in 45 m M Tris-borate, 1
m M EDTA (0.5X TBE) gels stained w ith ethidium brom ide.
Southern blot analysis (Southern, 1975) w as perform ed on PCR
positive mice using BamHI and EcoRI/Sail digested tail DNA. Biotinlabeled pILSHI served as the probe and the procedure follow ed the
instructions included in the Polar Plex® C hem ilum inescent Kit (M illipore).
D igested DNA w as subjected to electrophoresis in 1% 0.5X TBE agarose then
transferred by pressure blotting (Stratagene) to Immobilon-S® nylon
m em brane (Millipore). Prehybridization, hybridization, and
chem ilum inescent detection w ere carried out as described in the kit.
Some of the mice testing positive for Shiva 7 by PCR w ere bred to
norm al FV B /N an d Swiss-W ebster mice. Ft an d F2 generation mice w ere
screened for the presence of Shiva 1 DNA by PCR.
A random sam ple of the DNA-positive anim als along w ith norm al
FV B /N a n d Swiss-W ebster mice w ere tested for expression of IL2-Shiva 1
m RN A in in vitro cultured prim ary lym phocytes. Mice w ere sacrificed, a
tail sam ple taken, and spleens rem oved. Instrum ents w ere cleaned w ith
70% ethanol betw een each mouse. DNA w as extracted from the tail sam ple
as described above. U nder sterile conditions spleens w ere m inced in H ank's
buffered saline solution (HyClone Laboratories) and cell suspensions

38
transferred to centrifuge tubes. After pelleting, the cells w ere resuspended in
9 ml of sterile type 1 w ater and held for 20 sec to lyse red blood cells then 1
m l of sterile 10X phosphate buffered saline (PBS; HyClone Laboratories) was
ad d ed to bring the solution back to isotonic conditions. Large pieces of debris
w ere rem oved from the suspension and the rem aining cells pelleted.
D iscarding the supernatant betw een centrifugations, the cells w ere w ashed
twice in Hybri-Care® (American Type C ulture Collection) or RPMI-1640
(HyClone Laboratories) containing 10% fetal bovine serum (FBS; H yClone
Laboratories) then resuspended in 2 ml of Hybri-Care® or RPMI-1640 plus
10% FBS or Lym phocyte C ulture Fluid (Torres et al, 1993) a n d transferred to
35 m m suspension cell culture dishes (Sarstedt). G entam icin (Life
Technologies) to 0.1 m g /m l and hum an recom binant IL2 (Sigma or Life
Technologies) to 10 IU /m l w ere added to each culture. Cells w ere grow n
overnight at 37°C, 5% C 0 2 in air then split by volum e into tw o equal
portions. The total volum e of m edium was returned to 2 ml and
G entam icin and IL2 adjusted to the above concentrations. To one of each
p a ir of cultures, concanavalin A (ConA) w as added to a final concentration
of 3.25 |xg/m l. After an additional 48 h incubation, cells w ere counted and
harvested for RNA extraction. Cleared culture m edium w as frozen at -20°C
for later Shiva 1 detection.
Total RNA was extracted from 5 x 106 cells using Trizol® RNA
Extraction Reagent (Life Technologies) using the protocol included w ith the
product. The m ethod is based on guanidine isothiocyanate extraction
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developed by C hom azynski and Sacchi (1987). Barrier pipette tips,
diethylpyrocarbonate (DEPC) treated type 1 w ater, glassw are baked overnight
at 180°C, frequent changes of latex gloves, and new , autoclaved
m icrocentrifuge tubes w ere used to avoid cross contam ination an d
introduction of ribonucleases (RNase) into the solutions being handled.
RN A yield and concentration w as determ ined by absorption
spectrophotom etry at 260 nm assum ing 1 OD260= 40 p g /m l (Sam brook et al.,
1989).
One m icrogram or 0.6 pg of total RNA w as subjected to reverse
transcription PCR (RT-PCR). The m ethod used selects polyadenylated
m RN A from a pool of total RNA and converts it to DNA by reverse
transcription using a 15 base polydeoxythym idylate oligonucleotide prim er
(oligo15dT) and reverse transcriptase enzym e from avian m yeloblastosis
virus (AMV-RT). A portion of the IL2-Shiva 1 double stran d ed D N A from
the transcript w as then am plified using PCR and prim ers specific for this
target. Reverse transcription w as conducted in RNase-free w ater w ith 5 m M
M gC l2, RT Buffer (Promega), 1 mM each dNTP, 25 p i/m l rRN asin®
(Prom ega), 0.75 U /p l AMV-RT (Promega), and 0.025 n g /p l oligo15dT. Each
reaction had a total volum e of 20 pi and w as incubated at 42°C for 15 m in. A
parallel set of reactions to test for the presence of contam inating DNA
contained all ingredients except AMV-RT.
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The total reverse transcription reaction volum e w as u sed in a 100 |il
PCR w ith the addition of 4 |iil of 50 mM MgCl2/ 8 |il RT buffer, 20 pM ol of
each IL2TRANC and SHIVA1DN prim ers (Figure 3), 2.5 U Taq DN A
polym erase (Life Technologies), and 65.5 jxl RNase-free w ater. Reactions
w ere carried out at 94°C for 7 min; 40 cycles for 94°C for 15 sec, 56°C for 30 sec,
an d 72°C for 30 sec; then 72°C for 7 m in T em perature of the solution w as
d ro p p ed to and held at 4°C until gel electrophoresis.
Tail DNA w as tested w ith the IL2TRANC/SHIVA1DN p rim er set to
insure correct identification of transgenic anim als an d fidelity of the
reaction. Also, as a positive control of the ability of DNA extracted from
n egative control anim als to amplify, a set of prim ers for the m ouse
hom eobox 3 gene know n to be tightly controlled for expression only in
sperm atocytes d u rin g late meiosis and em bryos 11.5 to 12.5 d post coitum
(Figure 3; Rubin et al., 1986) w ere used following the above PCR conditions.
Five m icroliters of the RT-PCR and tail DNA PCR w ere evaluated on a 1.5%
0.5X TBE agarose gels stained w ith ethidium brom ide.
S upernatants of cell grow th m edium w ere cleared by centrifugation
(20000 x g) and evaluated for presence of Shiva 1 peptide by d o t blot using a
polyclonal antibody generated against Shiva 1 in rabbits (supplied by F.M.
Enright, Louisiana State U niversity) and a ELISAmate® Kit system w ith
alkaline phosphatase conjugated goat anti-rabbit IgG (K irkegaard an d Perry
Laboratories). Samples w ere applied in triplicate. Serial dilutions

containing from 0 to 4 |ig total synthesized Shiva 1 w ere used as controls.
TBS buffer (20 m M Tris, 0.5 M NaCl, pH 7.5) was used to prew et
nitrocellulose m em brane before assem bly in the do t blot a p p aratu s (BioRad).
Each w ell w as w ashed three times w ith TBS then 300 pi of sup ern atan t w as
a d d e d an d allow ed to flow by gravity through the m em brane. Vacuum w as
ap p lied for 1 h to dry the mem brane. Filtered Blocking Solution (K irkegaard
an d Perry Laboratories) w as applied to each well then rinsed twice w ith
W ash Solution (Kirkegaard and Perry Laboratories). Rabbit anti-Shiva 1
antibody at a 600:1 dilution in Milk Diluent (Kirkegaard and Perry
Laboratories) w as loaded into each well and incubated covered for 1 h before
being d raw n through the m em brane by vacuum . The m em brane w as
w ashed five tim es w ith W ash Solution. Goat anti-rabbit antibody
conjugated to alkaline phosphatase, diluted 600:1 in M ilk D iluent, w as
allow ed to interact w ith the contents of each well for 1 h. U nbound antibody
w as then w ashed through the m em brane by rinsing five tim es w ith W ash
Solution (Kirkegaard and Perry Laboratories). The m em brane w as rem oved
from the apparatus and exposed to BCIT/NBT® substrate (K irkegaard and
P erry Laboratories) for detection of alkaline phosphatase.

Detection

reactions w ere stopped by im m ersing the m em brane in room tem perature
w ater.

RESULTS AND DISCUSSION
SEQUENCING
A m ong the reaction sets using the three prim er pairs, the entire IL2Shiva 1 gene sequence w as determ ined (Figure 6). To attain a clear readable
sequence, the dried gel w as exposed to XAR radiographic film (Kodak) for 52
h. The long exposure time overexposed the M13 single stran d ed tem plate
reactions used as the control but it rem ained readable for over 150 bases.
The cloned sequence of Shiva 1 agrees w ith th at originally
pro g ram m ed (Figure 2). Band com pression in the sequencing gel in the G
an d C lanes resulted in a possible discrepancy. It appeared that a
transposition occurred betw een bases 79 and 80 turning Ala-27 to Arg-27 at
the beginning of the hydrophobic a-helix, w hich could have h ad a m ajor
im pact on activity. The discrepancy w as resolved, how ever, by the lanes
containing the inosine reactions. Band com pression w as relieved and the
sequence w as clearly correct.
A single base A to C transition w ithin the code for the IL2 signal
sequence w as discovered w hen com pared to the sequence published by Fuse
et al. (1984). This is the first base in the Leu-12 codon b u t the substitution did
no t effect the aa sequence (UUG to CUG). Also, an investigation of the
frequency of codons for Leu in m ouse IL2 found that UUG w as as com m on
as CUG. Therefore, the change should not adversely effect expression or
secretion of Shiva 1. All other sequence w as identical to th at rep o rted by
Fuse et al. (1984) and N ovak et al. (1990b).
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B T — AAAAC

QACOO

CCAOT

-599
OCCAA

OCTTO

CATOC

-590
gacaa

CTOCA

-580

cgaca

a a a ta

A CTCT

-5 7 0

g ta c c

-520

OOTCO

AOAOO

ATCCC

-560

C

a g tc

-550

-540

-5 3 1

tCA A G CTCAA CAAGC ATTTT AGGTG TCCTT AGCTT ACTAT TTCTC

-510

-500

-490

-480

-470

TGGCT AACTG TATGA AGCCA TCTAT CACCC TGTGT GCAAT TAGCT CATTG TGTAG ATAAG AAGGT

-4 6 0

-450

-440

-430

-420

-410

-401

AAAAC CATCT TGAAA CAGGA AACCA ATATC CTTCC TGTCT AATCA ACAAA TCTAA AAGAT TTATT

-390

-380

-370

-360

-350

-340

C T TT T CATCT ATCTC CTCTT GCGTT TGTCC ACCAC AACAG GCTGC TTACA GGTTC AGGAT GGTTT

-3 3 0

-320

-310

-3 0 0

-290

-280

-271

TGACA AAGAG AACAT TTTCA TGAGT TACTT TTGTG TCTCC ACCCC AAAGA GGAAA ATTTG TTTCA

-260

-2 5 0

-240

-230

-220

-210

TACAG AAGGC GTTCA TTGTA TGAAT TAAAA CTGCC ACCTA AGTGT GGGCT AACCC GACCA AGAGG

-200

-190

-180

-170

-160

-150

-141

GATTT CACCT AAATC CATTC AGTCA GTGTA TGGGG GTTTA AAGAA ATTCC AGAGA GTCAT CAGAA

-1 30

-120

-110

-100

-9 0

-8 0

GAGGA AAAAC AAAGG TAATG CTTTC TGCCA CACAG GTAGA CTCTT TGAAA ATATG TGTAA TATGT

-70

-60

-5 0

-40

-30

-20

-1 1

AAAAC ATCGT GACAC CCCCA TATTA T T T T T CCAGC ATTAA CAGTA TAAAT TGCCT CCCAT GCTGA

-1 + 1

+10

+20

+30

+40

+50

AGAGC TGCCT ATCAC CCTTG CTAAT CACTC CTCAC AGTGA CCTCA AGTCC TGCAG GCATG TACAG

+60

+70

+80

+90

+10 0

CATGC AGCTC GCATC CTGTG TCACA CTGAC ACTTG T G C tc c t t g t

caaca

+110
gcgca

a g a te

+119
ta C C A

+130
+140
+150
+160
+ 170
+180
TGCCG CGCTG GCGTC TGTTC CGCCG TATCG ACCGT GTTGG CAAAC AGATC AAACA GGGTA TCCTG
+190
+200
+210
+220
+230
+239
CCGTG CTGGC CCGGC TATCG CTCTG GTTGG CGACG CCCGC GCAGT TGGTT GAGAA
TTCO T

AATCA TOGTC

A T A QC

TQTTT

CCTOT

QTOAA

Figure 6. The sequence of pILSHI from the Universal prim er to the Reverse
p rim er (M13 vectors). U nderlined indicate the sequence of the Reverse and
U niversal prim ers. Sequences were readable w ithin 10 bases of the
prim ers. Lower case letters represent PCR prim er sequences used to extract
m ouse IL2 pro m o ter/en h an cer from genom ic DNA. Italics are Shiva 1
sequence. Bold face type are bases native to pUC18. O rigin (+1) is the
p resum ed start of transcription. Translation starts at +48.__________________

44
SCREENING OF FOUNDERS
Four h u n d red and thirty-eight FV B /N em bryos in tw o groups two
weeks apart w ere injected w ith the BamHI fragm ent of pILSHIX (Figure 5).
A total of 78 pups, 34 in the first group an d 44 in the second, w ere born in 12
litters averaging 6.5 p u p s/litte r (range: 4 to 10). PCR screening revealed a
total of 26 (six from the first group and 20 from the second group) of the 78
anim als (33%) carried Shiva 1 (Table 1; Figure 7). Palm iter and Brinster
(1986) reported that, typically, m ouse em bryo pronuclear injection produces
25% transgenics of the mice born so these results agree favorably w ith
historical proportions.

Table 1. Success rate of pronuclear injection of two groups of m ouse
em bryos
No. Embryos
N o. T ransgenic
G ro u p
Injected
No. Litters N o. Pups
(% of those born)
1
200
5
34
6 (18%)
2
238
7
44
20 (45%)

Southern blots of a set of BamHI digests of tail DNA from the
positive founders w ere inconclusive (data not show n). Faint positive bands
w ere disclosed in eight of the 28 lanes but they w ere m uch larger fragm ents
than expected having an approxim ate size of 5000 bp. A probe of a set of
EcoRI/Sall digests also revealed a large fragm ent of approxim ately 5000 bp in
11 sam ples. As before, these bands w ere very faint. The two sets overlapped
b u t three of the anim als found positive in the BamHI set w ere n o t positive

I anp

D iscription______________

1
2
3
4-12
13
14
15-17
18
19
20
21-24

0.28 jig pBR322 Haelll marker
FCR reaction #3 DNA
PCR reaction #12 DNA
PCR reaction #22-#30 DNA
BLANK
0.28 jig pBR322 Haelll marker
PCR reaction #32-#34 DNA
PCR reaction #6 DNA
PCR reaction of no template negative control
PCR reaction of pILSHIX/neo positive control
BLANK

Figure 7. Results of PCR am plification of DNA extracted from the tail tis
sue of potential transgenic mice. PCR utilized prim ers specific for Shiva 1
(SHIVA1UP/SHIVA1DN). The positive result w as a 125 b p fragm ent
am plified from DNA of m ouse #3 (lane 2), #12 (lane 3), #22 (lane 4),
#23(lane 5), #27 (lane 9), and #34 (lane 17). A positive control using
pILSHIX/neo as a tem plate also am plified a 125 bp fragm ent (lane 20).
N o-tem plate negative control w as loaded in lane 19 an d as expected had
no am plification of a specific fragm ent. The gels were 1.5% agaraose 0.5X
TBE stained after electrophoresis w ith 1 jig /m l solution of ethidium bro
m ide. Lanes are num bered sequenctially from left to right across the two
gels. Lanes containing PCR products w ere loaded w ith 10 pi of the 100 pi
total reaction volume.
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in the EcoRI/Sall set. A dditional exposure tim e d id no t clarify the results
d u e to high background.
EVALUATION OF TRANSGENIC LINES
Palm iter and Brinster (1987) found that due to delayed integration,
30% of transgenic mice produced by pronuclear injection are m osaics. Some
mosaics failed to carry the transgene in their germ cells and others displayed
som e degree of germ cell mosaicism. To test the transgenic lines for ability
to pass the transgene to offspring, eight founders w ere bred to norm al
FV B /N and Swiss-W ebster mice and the resulting litters screened for the
transgene using the IL2TRANC/SHIVA1DN prim er pair w hich yields a 235
b p fragm ent (Table 2). M ost did not differ significantly from the expected 1:1
ratio of norm ahtransgenics. Forty of the line 12 F2 generation, the result of
b reeding F /s to norm als, also displayed the expected norm al to transgenic
ratio (Figure 8). Two groups of progeny dem onstrated possible germ line

Table 2. Results of screening of F, generation from breeding of founders to
n o rm al m ates
F o u n d er N o
3
12
23
27
42
60
61
73

Sex
F
M
F
M
M
M
F
F

N o of Progeny
10
8
17
11
19
5
13
13

No. Transgenics
4
4
2
3
8
2
2
4

Differ8
*

*

aThose ratios of norm al:transgenic progeny w hich differed (P<.05) from the
expected 1:1 as determ ined by x2 analysis are indicated by an asterisk.
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44
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:----------
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Lane
1
2
3
4-12
13
14
15
16-35
36
37
38-48

25

Discription__________________
0.15 pg pUC18 Ddel marker
PCR reaction (-) control
PCR reaction #3 DNA
PCR reaction Line 12 Fj DNA
0.15 pg pUC18 Ddel marker
PCR reaction plLSHJ (+) control
PCR reaction (-) control
PCR reaction lin e 12 F1 DNA
PCR reaction pILSHI (+) control
0.15 pg pUC18 Ddel marker
PCR reaction Line 12 F1 DNA

Figure 8. Results of tail tissue DNA PCR am plification of offspring from
m atings of Line 12 Fj Shiva 1 positive and founder anim als to norm al
FV B/N mice. The IL2TRANC/SHIVA1DN prim er pair used for this
screening amplifies a 235 b p fragm ent of the transgene. Lanes are num 
bered from left to right across the two gels. Lanes 1,13, and 37 w ere
pUC18 Ddel m arkers w ith fragm ents of the sizes show n. Lanes 2 and 15
w ere no-tem plate negative controls. Lanes 14 and 36 w ere pILSHI-temp late positive controls. Lane 3 w as am plified genomic DNA from founder
#3, also as a positive control. The rem aining 40 lanes w ere am plified DNA
from 40 line 12 offspring; 18 of the 40 amplified a 235 bp band representing
the IL2/Shiva 1 gene from the start of transcription to the stop codon.
Electrophoresis m edium w as a Relient System precast 1% SeaKem Gold, IX
TBE, agarose gel containing 0.5 p g /m l ethidium brom ide (FMC). Lanes
containing PCR products w ere loaded w ith 5 pi of the 100 pi reaction vol
ume.
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mosacism . PCR of DNA from two of the offspring of Line 73 resulted in
am plification of a fragm ent sm aller than expected by approxim ately 400 bp
indicating a possible deletion m utation from the interior of the gene. A
second PCR using the IL2TRANC/SHIVA1DN prim er set (Figure 3)
pro d u ced no fragm ent indicating that the deletion included the start of
transcription.
Representatives of 15 lines plus norm al FV B /N an d Swiss-W ebster
strains w ere sacrificed to test for expression of IL2-Shiva 1 m RNA in ConAinduced spleen-derived lym phocytes (Figure 9). RT-PCR analysis revealed
tw o lines, Line 3 an d Line 12, dem onstrating induced m RN A expression.
N o specific PCR product w as detected in the negative controls. In Line 3, no
PCR p ro d u ct w as detected w hen the cells w ere not exposed to Con A b u t a
strong band w as detected after induction. This is in agreem ent w ith the tight
control docum ented for other genes controlled by the IL2
p ro m o ter/en h an cer (Novak et al., 1990b, Emilie et al., 1989). H ow ever, in
Line 12, although there w as an increase in PCR p ro d u ct upon induction,
som e Shiva 1 mRNA w as produced in lym phocytes no t exposed to ConA,
an indication of in vivo induction.
ConA especially at 3.25 p g /m l is not considered to be a strong inducer
of IL2 expression yet a definite mRNA induction w as m easured in these two
lines.

C oncentrations as high as 25 p g /m l have been used on T cell

lym phom as to induce m axim al expression of IL2 enhancer-controlled
reporter genes (Gillis et al., 1980; Fujita et al., 1986; Emilie et al., 1989).
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1^235
I \l6 6 b p ^
Lane
1

Discription
0.56 pg
pg pBR322
pBR322 Haelll
Haelll marker
marker
0.56
PCR: No template (-) control
PCR: FVB/N, MH3 primers
PCR: FVB/N
PCR: pILSHI (+) control
PCR: Line 3
PCR: Line 12
0.15 pg pUC18 Ddel marker

reactions
without

It

t

t

t

reverse
tran
scriptase

Lane Discripfon
1 & 13 0.15 pg pUC18 Ddel marker
2 & 14 PCR: pILSHI (+) control
3 & 15 RT-PCR: No template (-) control
4 & 16 RT-PCR: FVB/N resting
5 & 17 RT-PCR: FVB/N induced with ConA
6 & 18 RT-PCR: Line 3 resting
7 & 19 RT-PCR: Line 3 induced with ConA
8 & 20 RT-PCR: Line 12 resting
9 & 21 RT-PCR: Line 12 induced with ConA
10 & 22 RT-PCR: Line 73 resting
11 & 23 RT-PCR: Line 73 induced with ConA
12 & 24 BLANK

Figure 9. Results of PCR screening of Lines 3,12, and 73 both for the pres
ence of DNA and RNA. Prim er pair w as IL2TRANC/SHIVA1DN unless
otherwise noted. Gel m edium w as 1.5% agarose 0.5X TBE stained after elec
trophoresis w ith a solution of 1 p g /m l ethidium bromide. W hite arrow s
an d num bers identify lanes. A: PCR products generated by am plification of
DNA extracted from tail tissue using IL2TRANC/SHIVA1DN prim er p air
sum m arizing the tail screening data. Lines 3 and 12 (lanes 6 and 7, respec
tively) w ere positive. A fragm ent of FV B/N DNA w as am plified w ith M H3
prim er pair (lane 3) b u t no t w ith IL2TRANC/SHIVA1DN prim er pair (lane
4). Lane 2 w as the no-tem plate negative control, lane 1 the pBR322 H aelll
size marker, and lane 8 the pUC18 D del size marker. Bj: PCR products gen
erated by amplification of reverse transcribed total RNA from lymphocytes
that w ere either resting o r induced to produce IL2 using ConA. No
detectable product was form ed from Line 3 w hen not exposed to ConA
(lane 6) b u t a strong band of the predicted 123 bp w as found w hen RNA
w as extracted after 24 h exposure to the m itogen (lane 7). Line 12 unin
duced lymphocytes w ere found to have a low level of expression im plying
in vivo induction (lane 8) b u t that level increased upon 24 h exposure to
ConA (lane 9). B2: Parallel reactions to those in B2 b u t w ithout reverse tran
scriptase. There w as no detectable product from any of the RNA extractions
indicating no contam inating DNA in the preparations.

H ow ever, Gillis et al. (1980) reported only 4% of LBRM-33 cells rem ained
viable after treatm ent w ith 20 (ig/m l ConA. In contrast, 87% rem ained
viable at 2 (ig/m l. The ten-fold increase in ConA resulted in a 48.9-fold
increase in IL2 activity. O f the m itogens tested (phytohem aglutinin-A
(PHA), ConA, and phorbol m yristate acetate (PMA) an d com binations of
these), only ConA at 2 p g /m l and PHA at 0.1% induced som e activity w hile
allow ing over 87% of the cells to rem ain viable.

It w as a concern that

expression of Shiva 1 w ould be toxic to the lym phocytes and th at
stim ulation w ith lethal concentrations of ConA w ould m ask th at effect.
Therefore, it w as determ ined that a low but still effective dose of ConA
w o u ld be used and no effort w as m ade to titer ConA stim ulation m axim ize
induction of IL2.

N o apparent adverse effects w ere noted in any of the

lym phocyte cultures, including controls, w ith the low level of C onA used.
The reason for the uninduced expression in Line 12 w as not
investigated.

It is likely that som e activated T cells w ere present in the

culture before addition of ConA. This im plies that the gene w as induced in
vivo in response to natural stim ulus even though the cells h ad been in
culture for over 48 h, time enough for term ination of native IL2 expression.
H ow ever, native IL2 expression is controlled not only at the transcriptional
level b u t also by rapid mRNA degradation signaled by elem ents in the 3'
u n tran slated region u p o n rem oval of cytokine-inducing stim uli (M ather,
1989; T routt an d Kelso, 1992). This region w as om itted in 1L2-Shiva 1 an d
replaced w ith SV40 sequence w hich should lengthen the half life of the
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transcript over th at of native IL2. If Shiva 1 transcription w as the result of
in vivo induction, it w ould m ean that helper T cell targeted expression of a
transgene in vivo is possible using the IL2 p ro m o ter/en h an cer at least w hen
linked to Shiva 1 an d the SV40 polyadenylation signal.
H ow ever, induction and level of expression of stably integrated
transgenes is unpredictable. C onfiguration of the chrom osom e at the site of
integration, copy num ber of the transgene, and flanking sequences m ay all
p lay a role. A lthough the know n specific controlling regions of m ouse IL2
w ere included in the gene, interaction w ith the site of integration m ay have
resulted in low level expression in Line 12 in the absence of any stim ulation.
A n assay for IL2 levels w ould have been valuable at this point as a
d eterm in an t of the extent T cell activation in the absence of ConA.
D ot blot antibody detection of Shiva 1 in su pernatant a n d crude cell
lysate of induced lym phocytes w as unsuccessful. Excessive background
especially for cultures grow n in Lym phocyte C ulture Fluid (Torres et al.,
1993) p revented definitive results. Supply of antibody w as very lim ited
p u ttin g som e constraints on developm ent of efficient m ethodology an d
attem pts by F.M. Enright to produce additional antibody have been
unsuccessful (personnel comm unication). The low er lim it of detection w as
125 ng of Shiva 1 or the equivalent of 80 nM.
U npublished data (F.M. Enright, personal com m unication) indicates
th at lytic activity is associated w ith difficulty in detection of peptide w ith
antibody w hen expressed as genes in fish, whereas, inactive peptide is

readily detected in baculovirus insect systems. It has been dem onstrated that
the am phipathic a-helix of apolipoprotein, m elittin, and cecropin A interact
strongly w ith cell m em branes and this interaction is vital to activity.
A ntibody against Shiva 1 w as generated from synthesized peptide. It is
possible that h ap ten necessary for antibody binding is unavailable in active
Shiva 1 d u e to com petition by m em brane proteins w hereas inactive peptide
is free to associate w ith antibody. This m ay not be the case, how ever, in
plants. Jaynes et al. (1993) docum ented the presence of Shiva 1 peptide by
w estern blot in tobacco plants w ith enhanced disease resistance.

CONCLUDING REMARKS
These results do not m ark an end b u t a beginning; they are the first
steps in investigating the targeted expression of a cecropin. The prom ise of
these b ro ad spectrum antim icrobials is enorm ous. They can destroy
transform ed cells, enveloped viruses, and m any protozoan an d bacterial
pathogens including obligate intracellular parasites yet are non-toxic to
norm al healthy cells at concentrations >10 tim es th at needed for lytic activity
against bacteria. Their small size m ake them easy to synthesize to
investigate the im pact that sm all changes in aa com position w ill have on
specificity a n d activity against specific cells. The small size also allow s
synthesis of genes for novel peptides w hose toxicity and lytic activity m ay be
tailored for specific targeted expression systems.
The germ -line transgenic m ouse is just a m odel useful for evaluating
the effectiveness and safety of the cecropins w hen expressed in lym phocytes.
If these are show n to be satisfactory, the possibilities become endless. As
m ore is learned about enhancers, expression m ay be targeted to m acrophages
for activity earlier in the im m une response or to platelets for release at the
site of a w ound. Tum or infiltrating lym phocytes, already stu d ied as a
vehicle for targeting toxins like tum or-necrosis factor to m alignant tum ors,
m ay be engineered to deliver cecropins. Diseases such as m alaria and
brucellosis, w hich have been difficult to control, m ay be susceptible to gene
therapy using cecropins. Domestic anim als could be m ade generally m ore
disease resistant allowing a reduction in the use of antibiotics, w hich m ay, in
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turn, retard bacterial evolution tow ard resistance to these valuable
therapeutics.
In addition, this research has proven the feasibility of targeting
expression of a synthetic gene to lym phocytes even if lytic peptides do not
live u p to their prom ise. Lymphocyte targeted expression alone could have
b ro ad application in im m unology and m edicine using other synthetic or
n atu ral genes.
The research w ith the transgenic lines continues. There are currently
19 individuals from Line 12 being tested against FV B /N norm al mice an d
Line 73 mice in Dr. Frederick Enright's laboratory at Louisiana State
U niversity for resistance to Brucella abortus. Several litters have been born
w ithin the past m onth from both Line 3 and Line 12 parents and detection of
active p eptide in lym phocyte cell lysate and supernatant will be pursued.
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APPENDIXES

PRIMARY AND SECONDARY STRUCTURE OF
SHIVA 1 A N D CECROPIN B
RESTRICTION MAP OF pILSHIX
RESTRICTION M AP OF pILSHIX/neo
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P/E murine
Interleukin-2
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PstKlOSO)
Sphl(1095)
HincIId 137)
BglII(1147)
EcoRI(1274)
BstBI(1277)
Ball(1283)
NcoI(1286)
StyKl 286)

Ppal(3551)

Shiva 1

SV40PolyA
& splice

ColEI on

AatII(1292)
AhaII(1292)

lac I*
AflIII(2590)
Asel(2584)
Pvu11(2577)
Asel(2525)
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(2208)
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Restriction Map of pILSHIX
4471 base pairs
Derived from pILSHI (from pUC18) and pMSG via pSL1190

67

AatII(5527)

Ndel(183)
Narl(235)

HindIII(400)

sphl(410)

Xmnl(52 0 4 ? f<5411)\
Scal{5087)
'

Pstl(416)
Sall(4l8)

CfrlOI(4689)
Ppal{4676)
neo expression
cassette
EcoRI(l387)
HincII(l566)

P/E murine
Interleukin-2
AflIII(3715)
Nhel(3337)
Sphl(3333)
PVUIC3306)
BglII(3295)
BamHI(3268)

SV40 Poly A
& splice

Shiva-1

Pstl(2205)
Sphl(2220)

HincII(2262)
BglII(2272)
EcoRI(2399)
XhoI(2417)

Restriction M ap of pILSHIX/neo
5605 bp
Derived from pILSHIX and neo cassette from pMCIneoPolyA

VITA
W illiam A. Reed w as bom in N ew ark, N ew Jersey, A ugust 10,1950
an d w as educated through high school in H opedale, M assachusetts
g rad u ating from H opedale Junior and Senior H igh School in June of 1968.
H e atten d ed N ortheastern U niversity m ajoring in Chem ical E ngineering
from 1968 to 1972 then m oved to Bozeman, M ontana w here he found a
passion for anim al agriculture. Transferring credits to M ontana State
U niversity an d changing m ajors to A gricultural Science, he received his BS
in 1976. W hile at M ontana State he w as aw arded the M iller M em orial
H orsem anship for his w ork w ith that specie.
Between 1976 and 1986 he w orked in agriculture as ranch hand,
forem an, an d m anager on livestock enterprises until his n atu ral scientific
interest took him back to M ontana State University and a MS degree in
A nim al Science/A nim al Breeding and Genetics u nder Dr. D onald Kress in
1988.
He enrolled at Louisiana State University in the fall of 1988 u n d er the
A gricultural Biotechnology Fellow ship program electing to m ajor in
A nim al Science w ith a m inor in Biochemistry w orking u n d er the guidance
of Dr. K enneth W hite, D epartm ent of Animal Science, and Dr. Jesse Jaynes,
D epartm ent of Biochemistry, on applications of synthetic lytic peptides.
A fter com pleting all course w ork and passing his general exam ination he
m oved, at Dr. W hite's invitation, to U tah State U niversity w here Dr. W hite
h ad accepted a faculty position.

There he com pleted his dissertation

68

research w hile w orking full time as Dr. W hite's laboratory technician and
m aintaining his ties to LSU for the purpose of receiving his degree.
H e has authored three peer-review ed publications on em bryo and cell
culture and presented three abstracts at various scientific m eetings. H e has
also been an active collaborator co-authoring several papers and abstracts
originating in Dr. W hite's laboratory at U tah State U niversity dealing w ith
oocyte activation, em bryo culture, and em bryonic stem cell culture. H e is co
inventor w ith Dr. W hite and Dr. John M orrey of U tah State U niversity on a
p a te n t application dealing w ith targeted expression of lytic peptides.
Bill is m arried to the form er Lorraine G. Racicot of N o rthham pton,
M assachusetts and has one son, Jason, born Septem ber 5, 1978.

DOCTORAL EXAMINATION AND DISSERTATION REPORT

Candidate: w1111am A> Reed
Major Field: Animal Science
Title of Dissertation:

Interleukin 2 Promoter/Enhancer Controlled Expression

of a Synthetic Cecropin-Class Lytic Peptide in Transgenic Mice

Approved:

i f l o r aand
n d Chairman
G h a im u in
jor Professor

Graduate School

EXAMINING COMMITTEE:

h

J

Date of Examination:

flrtnher 23, 1995

ir

JJLJL

w

